Lysyl oxidase expression is regulated by the H3K27 demethylase Jmjd3 in tumor-associated M2-like macrophages.

M2-like macrophages epigenetics lysyl oxidase

Journal

Journal of clinical biochemistry and nutrition
ISSN: 0912-0009
Titre abrégé: J Clin Biochem Nutr
Pays: Japan
ID NLM: 8700907

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 30 07 2019
accepted: 05 09 2019
entrez: 2 4 2020
pubmed: 2 4 2020
medline: 2 4 2020
Statut: ppublish

Résumé

Copper is one of the essential micronutrients, and copper-containing enzymes contribute to crucial functions in the body. Lysyl oxidase is a copper-containing enzyme that remodels the extracellular matrix by cross-linking collagen and elastin. The overexpression of lysyl oxidase was recently shown to promote tumor metastasis. M2-like macrophages were also found to significantly accumulate in the tumor microenvironment, and correlated with a poor patient's outcome. We speculate that M2-like macrophages promote tumor progression via lysyl oxidase expression. Epigenetics, a mitotically heritable change in gene expression without any change in DNA sequencing, is also associated with tumor progression. However, the relationship between lysyl oxidase expression in M2-like macrophages and epigenetics remains unclear. Lysyl oxidase expression was significantly induced in human leukemic THP-1 cell-derived M2-like macrophages. Furthermore, the level of histone H3 tri-methylation at lysine 27 was decreased, and a pre-treatment with a H3K27 demethylase inhibitor notably suppressed lysyl oxidase expression in M2-like macrophages. Lysyl oxidase derived from M2-like macrophages also enhanced breast cancer cell migration, and this was suppressed by a H3K27 demethylase inhibitor. The present results suggest the mechanism of lysyl oxidase expression in M2-like macrophages as an aspect of epigenetics, particularly histone methylation.

Identifiants

pubmed: 32231406
doi: 10.3164/jcbn.19-67
pii: DN/JST.JSTAGE/jcbn/19-67
pmc: PMC7093300
doi:

Types de publication

Journal Article

Langues

eng

Pagination

110-115

Informations de copyright

Copyright © 2020 JCBNCopyright © 2020 JCBN.

Déclaration de conflit d'intérêts

No potential conflicts of interest were disclosed.

Références

Int J Mol Med. 2018 Dec;42(6):3395-3403
pubmed: 30320350
Cancer Res. 2002 Sep 1;62(17):4854-9
pubmed: 12208730
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19507-12
pubmed: 24218578
Nutr Rev. 2004 Feb;62(2):60-4
pubmed: 15080367
Cancer Biother Radiopharm. 2012 Dec;27(10):672-7
pubmed: 23140307
Cancer Cell. 2009 Jan 6;15(1):35-44
pubmed: 19111879
Oncotarget. 2014 May 15;5(9):2736-49
pubmed: 24811362
J Surg Oncol. 1991 Mar;46(3):178-81
pubmed: 2011029
Clin Epigenetics. 2018 Jun 15;10:78
pubmed: 29983831
Cancer Res. 2006 Jan 15;66(2):605-12
pubmed: 16423985
Carcinogenesis. 2000 Sep;21(9):1761-5
pubmed: 10964110
J Clin Oncol. 2001 Feb 15;19(4):1118-27
pubmed: 11181677
Trends Immunol. 2010 Jun;31(6):220-7
pubmed: 20538542
ScientificWorldJournal. 2014 Jan 21;2014:521754
pubmed: 24578639
Free Radic Biol Med. 2013 Aug;61:197-205
pubmed: 23602908
Cancer Res. 1997 Jun 1;57(11):2229-37
pubmed: 9187126
Nat Rev Genet. 2002 Jun;3(6):415-28
pubmed: 12042769
Cancer Microenviron. 2012 Dec;5(3):261-73
pubmed: 22528876
Oxid Med Cell Longev. 2016;2016:1284372
pubmed: 27127545
Free Radic Res. 2008 Nov;42(11-12):949-56
pubmed: 19031313
Nat Med. 1995 Jul;1(7):686-92
pubmed: 7585152
Gastric Cancer. 2016 Apr;19(2):431-442
pubmed: 26100130
J Cell Physiol. 2017 Dec;232(12):3468-3480
pubmed: 28098359
J Cell Biochem. 2002;85(1):92-100
pubmed: 11891853
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Oncotarget. 2016 Nov 1;7(44):71673-71685
pubmed: 27765933
Eur J Vasc Endovasc Surg. 2012 Nov;44(5):491-7
pubmed: 22975154
Breast Cancer Res. 2006;8(4):R38
pubmed: 16846527
Nat Immunol. 2010 Oct;11(10):936-44
pubmed: 20729857
Cell Res. 2007 Oct;17(10):850-7
pubmed: 17923864
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17460-5
pubmed: 23033492
Cancer Res. 2016 Jan 15;76(2):188-92
pubmed: 26732355
J Clin Cell Immunol. 2015 Dec;6(6):
pubmed: 26962470
PLoS One. 2009;4(5):e5620
pubmed: 19440335
Oncol Lett. 2017 Nov;14(5):5791-5800
pubmed: 29113209
J Clin Biochem Nutr. 2018 Jul;63(1):58-65
pubmed: 30087545
Free Radic Res. 2018 Jul;52(7):799-807
pubmed: 29842805
Int J Mol Sci. 2017 Apr 20;18(4):
pubmed: 28425924
Sci Rep. 2016 Sep 26;6:33783
pubmed: 27666810
EMBO J. 2003 Oct 15;22(20):5323-35
pubmed: 14532106

Auteurs

Ryuhei Takemoto (R)

Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan.

Tetsuro Kamiya (T)

Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan.

Hirokazu Hara (H)

Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan.

Tetsuo Adachi (T)

Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan.

Classifications MeSH